Editorial review pending — noindex
This page remains under independent editorial review (reviewPending). It is visible in the wiki but noindexed until identity and primary-source framing pass that gate. It is not dosing, safety, or approval guidance.
Section 1 of 9Overview
Overview
Pentadeca-arginate (PDA) is a commercial and patent-facing name for the same 15-amino-acid sequence as BPC-157 (bepecin), supplied as an arginine salt rather than as the free base or acetate. Preferential patent language describes bepecin di-L-arginine (peptide:base ≈ 1:2), abbreviated Arg-BPC; other molar ratios (1:1 or 1:3) and alternative basic amino acids (lysine, ornithine) appear in the same patent family.
It is not a new covalent peptide analog. The active moiety in FDA terminology is still the BPC-157 sequence; what changes is the counter-ion and therefore the bulk drug substance identity.
Evidence boundary
Preclinical literature for tissue repair, GI models, and angiogenesis generally describes the BPC-157 sequence, not a head-to-head, peer-reviewed characterization of the arginate salt. A 2026-10-07 PubMed search on PDA-specific terms returned zero hits. Treat sequence-level animal data as not automatically transferable to a named PDA bottle without batch identity (COA) and salt-specific evidence.
Section 2 of 9Identity
Identity
| Property | Finding | Limit |
|---|---|---|
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Same as BPC-157 / bepecin (US9850282B2 SEQ ID NO:1) |
| Chemical type | Salt form (arginine counter-ion) | Not a new covalent analog |
| Preferred patent salt | Bepecin di-L-arginine (Arg-BPC) | Inventor patent claim |
| PubChem for "pentadecaarginate" | Not found (2026-10-07) | Name has no dedicated CID |
| Free-base peptide | CID 9941957; CAS 137525-51-0; MW ~1419.5 | PubChem |
| Acetate (FDA briefing) | CAS 216441-37-1 | Distinct BDS from free base |
| Separate CAS for arginate | Not identified in the dossier search | Open gap |
Product-to-product identity (exact stoichiometry, L- vs D-arginine, purity) is batch-dependent and cannot be inferred from the trade name alone.
Section 3 of 9Arginate vs acetate / free base
Arginate vs acetate / free base
What is the same: the peptide sequence (and therefore the putative active moiety).
What differs: the counter-ion; solubility, solution pH, and storage behaviour may differ as a formulation question. FDA's July 2026 PCAC materials treated free base and acetate as distinct bulk drug substances and voted on them separately. Arginate / PDA / Arg-BPC does not appear on that question list.
Patent stability tables (inventor data only)
US9850282B2 (granted 2017-12-26) reports applicant experiments summarising, among other comparisons, better dry-state and artificial-gastric-juice recovery for Arg-BPC than for acetate under the patent's conditions. Those figures are inventor data inside a patent, not an independent peer-reviewed replication. They must not be restated as established clinical or laboratory fact.
There is a narrative tension with older BPC-157 reviews that describe the peptide as stable in gastric juice for many hours without specifying salt form. Without a validated head-to-head method on identified salts, neither narrative should be treated as settled.
Section 4 of 9Pharmacokinetics and marketing claims
Pharmacokinetics and marketing claims
| Source | What it actually measures | Applies to PDA? |
|---|---|---|
| He et al., Front. Pharmacol. 2022 | IV/IM BPC-157 in rat and dog; short t½; IM bioavailability figures | No — not stated as arginate; not oral |
| NCT02637284 (PCO-02) | Planned oral safety/PK of "BPC-157 / bepecin" 1 mg tablets | Status unknown; no results posted; salt not specified as arginate |
| Vendor "~90% oral bioavailability", "~1000× stability" | Marketing | Not verified in peer review |
Human PK for PDA: not identified in the reviewed dossier. Do not cite vendor bioavailability or "1000×" figures as facts.
Section 5 of 9Regulatory context (BPC-157 salts — not PDA approval)
Regulatory context (BPC-157 salts — not PDA approval)
FDA briefing materials for the July 2026 Pharmacy Compounding Advisory Committee evaluated BPC-157 free base (CAS 137525-51-0) and BPC-157 acetate (CAS 216441-37-1). Staff recommended against listing; any advisory vote is not a final FDA rule. Because different salts are treated as distinct APIs, absence of arginate from that list is not an approval, exemption, or compounding green light for PDA.
This page does not assess legality for human use (legalityNotAssessed: true).
Section 6 of 9Claims vs evidence
Claims vs evidence
| Claim | Assessment |
|---|---|
| PDA = same peptide as BPC-157, different salt | Supported (patent + chemistry) — still needs batch COA for a given product |
| "~1000× better stability" | Not verified in independent peer review |
| "90% oral bioavailability" | Not verified |
| "Stable BPC-157" is clinically superior | Not verified |
| FDA allows PDA because it "is not BPC-157" | Fallacy given salt-form logic; arginate not on the PCAC list |
| Patent proves clinical benefit | No — patents are not clinical evidence |
Section 7 of 9Relationship to BPC-157
Relationship to BPC-157
For sequence-level animal and in-vitro literature, regulatory history of free base/acetate, and the broader research picture, see BPC-157. This page exists to document the salt-form trade identity and the evidence gap specific to arginate.
Section 8 of 9What this page intentionally omits
What this page intentionally omits
- Any dosing regimen, reconstitution schedule, or "protocol"
- Vendor safety ratings or efficacy percentages
- Assertions that PDA is compounded-approved or clinically superior to acetate/free base
Section 9 of 9Editorial next step
Editorial next step
Lane: independent-source-verification / salt-form identity. reviewPending can drop only after editorial gate review; arginate-specific evidence level remains preclinical / absent until peer-reviewed or independent analytical comparisons appear.